4th November 2009: Novo Nordisk India, a leading diabetes care company, with a strong presence in haemostasis area, launched a new room temperature stable rFVIIa (NovoSeven®) formulation, for Hemophilia with inhibitors. NovoSeven® has proven to be effective in the treatment of bleeding in hemophilia patients who develop antibodies (inhibitor patients).
The details can be read here.
No comments:
Post a Comment